Navigation Links
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Date:4/19/2009

greater, men became eligible for one booster infusion of either PROVENGE or placebo in accordance with the treatment arm to which they were randomized. Patients continue to be followed for the clinical endpoints of time to distant failure, which typically would be the appearance of a positive bone scan, and for overall survival.

About PROVENGE

PROVENGE (R) (sipuleucel-T), an investigational product in development for men with androgen-independent prostate cancer, may represent the first product in a new class of active cellular immunotherapies (ACIs). PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In controlled clinical trials, the most common adverse events were chills, fever, headache, fatigue, shortness of breath, vomiting and tremor. These events were primarily low grade with a short duration of 1-2 days following infusion.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases and approximately 28,660 men who were expected to die from the disease in 2008. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
2. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
3. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
4. Dendreon Reports Third Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Dendreon Reports First Quarter 2008 Financial Results
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Force Microscopy (AFM) have been developed and are opening up ... interface. The NeedleProbes’ cylindrical geometry enables researchers to measure ... - all in a single force distance curve. , ... ... constant diameter NeedleProbes are enabling unique measurements at ...
(Date:12/15/2009)... LONDON, Dec. 15 Thomson ... Pharma ® has become the first drug pipeline ... and outcome information. This highly anticipated new content ... this month. ,, Thomson Pharma ... from registries, publications, press releases, conferences, and other ...
(Date:12/14/2009)... 14 Dyadic International, Inc. (Pink Sheets: ... its collaboration with The Scripps Research Institute ("Scripps") ... re-annotate the genome of Dyadic,s patented and proprietary ... continuation of the successful relationship between the two ... engaged Scripps to annotate the C1 genome for ...
(Date:12/14/2009)... Calif., Dec. 14 Nektar Therapeutics (Nasdaq: ... has been appointed to serve on its board ... industry leader with over 35 years of experience ... "Dennis brings to Nektar extensive industry perspective at ... Howard W. Robin, President and CEO of Nektar ...
Breaking Biology Technology:New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3
... LAVAL, QC, April 14 /PRNewswire-FirstCall/ - Neptune Technologies ... and financial results for the fiscal 2008 third ... provided an update on recent,strategic milestones achieved., ... period ended February 29,2008 compared to the three-month ...
... FRAZER, Pa. and MAISONS-ALFORT, France, April 14 /PRNewswire-FirstCall/,-- ... that the European,Commission has granted marketing authorization for ... indicated for the treatment of,breakthrough cancer pain (BTCP) ... therapy for chronic pain. The approval allows Cephalon,to ...
... form basis of blood-based ColonSentry(TM) test -, ... GEN),a company focused on developing blood-based biomarker tests ... management, today reported,positive performance results from a large ... assessment of a patient,s current risk for,colorectal cancer. ...
Other Biology Technology:Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones 2Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones 3Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones 4Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
(Date:12/14/2009)... 14 MODA Technology Partners, a global ... and product testing for the Pharmaceutical industry, today ... company,s third generation mobile data acquisition platform. The ... further automate their regulated manufacturing processes. ,, ... Fully-Configurable Test Methods: Each test ...
(Date:12/13/2009)... about how a popular class of drugs used ... previously hidden components of chemical communication in the ... the illness, people with schizophrenia also struggle to ... order, difficulties that interfere with their ability to ... Schroeder, a student in the medical scientist training ...
(Date:12/13/2009)... at The Scripps Research Institute have solved a ... an ancient family of enzymes can have two ... to providing guidance for understanding other molecules in ... for the protein,s possible use for combating diseases ... was published in the December 13, 2009 advance, ...
Breaking Biology News(10 mins):MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3Not On Our Watch Grant to UNICEF to Support Critical Protection Programs for Zimbabwean Refugee Children 47645 1Not On Our Watch Grant to UNICEF to Support Critical Protection Programs for Zimbabwean Refugee Children 47645 2Not On Our Watch Grant to UNICEF to Support Critical Protection Programs for Zimbabwean Refugee Children 47645 3New study shows people with mental health problems receive inadequate medical care 47641 1New study shows people with mental health problems receive inadequate medical care 47641 2Genetically corrected blood cells obtained from skin cells from Fanconi anemia patients 8697 1Genetically corrected blood cells obtained from skin cells from Fanconi anemia patients 8697 2
... both the USA and the UK over the years and ... body mass index (BMI). However, many of the review methodologies ... scientific analysis of a nationally representative sample of childrens diets ... drinks children consume and their body weight. , UK ...
... humans almost certainly walked upright on two legs but may ... modern man, new research suggests. , The University of Manchester ... Advancement of Science) Festival of Science in York on Tuesday ... as modern chimps and gorillas do, then their ability to ...
... be understood using artificially-intelligent computer agents that mimic their ... of Philosophical Transactions of the Royal Society B and ... , Scientists using agents programmed with simple instructions ... whilst others are egalitarian - overturning previous theories developed ...
Other Biology News:Soft drinks alone do not affect children's weight 2Was ability to run early man's Achilles heel? 2Was ability to run early man's Achilles heel? 3Primate behavior explained by computer 'agents' 2
Request Info...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... FLA-7000 excels at fluorescent and radioisotopic image ... features four easy-to-access filters (filters of Y520, ... Imaging Plates) for upgrading flexibility. In addition, ... four kinds of excitation laser beams. ,The ...
... The Microarray Gene Frame® has been ... These frames feature the same dual ... Gene Frame® range for easy removal ... uniformity and there are three sizes ...
Biology Products: